Refine your search

Search Results within category "Lung Disease & Asthma"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Lung Disease & Asthma"


11 Study Matches

A Phase 4 Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of H.P. Acthar Gel in subjects with Pulmonary Sarcoidosis

This study is looking for patients who have persistent pulmonary sarcoidosis despite taking medicines (steroids and/or other medicines) to treat pulmonary sarcoidosis. The purpose of this research study is to find out if Acthar works well in and is safe when used as part of the treatment for Pulmonary Sarcoidosis. This research study will collect additional data as to the effectiveness and safety of Acthar in Pulmonary Sarcoidosis, and will examine how the study drug acts in the body and how well it manages symptoms of Pulmonary Sarcoidosis as well as some extra pulmonary manifestations. Patients are being asked to consider participating in this study because they are currently on prednisone to manage their Pulmonary Sarcoidosis and are still experiencing symptoms.
MaryCatherine Hess at mhess@pennstatehealth.psu.edu or 717-531-3779
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03320070
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Have symptoms of pulmonary sarcoidosis despite treatment
Taking 5-40 mg of prednisone for pulmonary sarcoidosis
Be willing to inject study medication at home
Taking a stable dose of prednisone for 4 weeks
Exclusion Criteria:
Have a diagnosis of pulmonary arterial hypertension
History of scleroderma, osteoporosis, congestive heart failure
History of peptic ulcer requiring treatment or GI bleed within past 24 weeks
Recent major surgery within past 24 weeks
Uncontrolled diabetes, hypertension
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

This study is for patients 40-80 years of age with IPF (idiopathic pulmonary fibrosis). This study is being done to learn more about an experimental medication which is being developed to treat fibrosis or scarring of the lungs. The purpose of this study is to evaluate the safety of this experimental medication when administered at two dose levels compared with placebo (injection containing no active medication).
Donna Griffiths at dgriffiths@pennstatehealth.psu.edu or 717-531-5519
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03538301
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 40-80 years of age
Have a diagnosis of IPF within the past 5 years
Unchanged dose of pirfenidone or nintedanib for at least 12 weeks if currently taking these medications
Exclusion Criteria:
Respiratory exacerbation or hospitalization in the last 3 months
Taking both pirfenidone and nintedanib simultaneously in the past 12 weeks
Lung transplant anticipated during the study
Known history of liver cirrhosis
Active smoker or cessation in the past 12 weeks
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Randomized trial of low nicotine cigarettes plus electronic cigarettes in smokers

This study will examine the health effects of lowering the nicotine content in cigarettes while having access to an electronic cigarette.
All
18 year(s) or older
This study is also accepting healthy volunteers
NCT04058717
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 21-70
Smoke 5 or more cigarettes per day
Must be willing to both switch to a different type of cigarette and try an electronic cigarette
No serious quit attempt or use of smoking cessation medication in the past 30 days
Meet diagnostic criteria for current or lifetime mental health condition
Exclusion Criteria:
Women who are pregnant, nursing, or trying to become pregnant
Any known allergy to propylene glycol or vegetable glycerin
History of difficulty providing blood samples
Other member of the household currently participating in the study
Unstable or significant medical condition in the past 3 months
Addiction & Substance Abuse, Lung Disease & Asthma, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site For VIOLET

Site For VIOLET
Nancy Campbell RN at ncampbell1@pennstatehealth.psu.edu or 717-531-1707, ext=3
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Admission to ICU with acute risk factors for Acute Respiratory Distress Syndrome (ARDS): Pneumonia, Aspiration, smoke inhalation, lung contusion, hypoxemia, intubation
shock
sepsis
pancreatitis
Vit. D deficiency
Exclusion Criteria:
unable to take Vit D by mouth
blood Calcium levels > 10.2
known kidney stone in past 1 year
Do Not Rescusitate orders (DNR)
prisoner
Infectious Diseases & Immune System, Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Evaluating the Cough Reflex in Fibrotic and Healthy Lungs

Determining cough threshold in patients with fibrotic lung disease and in healthy controls by stimulating cough.
Timothy Sheehan at tsheehan@pennstatehealth.psu.edu or 717-531-2925
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
40 years of age or older
Patient Group: Fibrotic lung disease with chronic cough symptoms or Idiopathic cough syndrome
Healthy Control Group: no cough (either chronic or acute)
Exclusion Criteria:
Recent history of smoking (former smokers must be tobacco-free for at least 1 year)
History of (other) lung diseases
History of uncontrolled gastroesophageal reflux disease (GERD)
Use of exclusionary medications (i.e. steroids, ACE inhibitors, narcotics, cough suppressants)
History of uncontrolled post nasal drip
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis

This study is for patients with IPF (Idiopathic Pulmonary Fibrosis) to see how well a new medication works with current standard treatment on lung function and IPF disease in general.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03711162
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 40 or greater
Diagnosis of Idiiopathic Pulmonary Fibrosis (IPF) within the past 5 years
Exclusion Criteria:
HIV or hepatitis B or C diagnosis
History of malignancy within the past 5 years
Acute IPF reoccurrence in the past 6 months
Lower respiratory tract infection in the past 4 weeks requiring antibiotics
History of lung volume reduction surgery or lung transplant
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Abdominal Binders to Compensate for Neurogenic Restrictive Lung Disease in Adults with Spinal Cord Injury

This research is being done to find out if the use of abdominal binders improves lung function, phonation (vocal sounds), and singing in individuals with SCI.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Cervical or Thoracic Spinal Cord Injury
Ages 18-75
ASIA A or B
Exclusion Criteria:
Ventilator dependent
Cystic Fibrosis
COPD
Lung Disease & Asthma, Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

SAV005-04 "A Phase III, randomized, double-blind, placebo-controlled study of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in cystic fibrosis patients

This is a study that will examine any benefits to use cycles of inhaled vancomycin compared to placebo. Analysis of the information will include lung function results, sputum or throat culture results, questionnaires, and time to use additional antibiotics up to 48 weeks. After the first 24 weeks, all subjects can receive open label study drug for the remaining 24 weeks. There are 13 study visits spanned over 48 weeks.
Diane Kitch at dkitch@pennstatehealth.psu.edu or 717-531-5646
All
All
This study is NOT accepting healthy volunteers
NCT03181932
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
6 years old and greater
Must have Cystic Fibrosis (CF)
Positive culture for MRSA at screening
FEV1 between 30-90%
Commit to 14 visits over 12 months
Exclusion Criteria:
You may not have allergies to vancomycin
Abnormal liver or kidney function
Inability to tolerate inhaled products
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Randomized, Placebo-Controlled, Double-Blind, Six Months Study Followed by an Open-Label -Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

The purpose of this research study is to evaluate the effectiveness and safety of MN-001(tipelukast) in subjects with IPF.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02503657
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
diagnosis of pulmonary fibrosis
presence of stage I-III defined by GAP index
Exclusion Criteria:
expected to receive a lung transplant in the next 12 months
known explanation for interstitial lung disease
ongoing treatment with Esbriet
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Recruitment for Nicotine and Tobacco Related Research at Penn State Hershey

The purpose of this project is to screen potential participants for multiple research studies being conducted by tobacco researchers at Penn State Hershey. Since there are multiple IRB approved studies enrolling at Penn State Hershey with similar but not identical inclusion/exclusion criteria, it is more efficient for the researchers and participants to have one phone number to call initially for basic screening. After completing this, the participant can be redirected for more specific screening if they are found to be potentially eligible for one of the studies.
Candace Bordner at cbordner@phs.psu.edu or 844-207-4594
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 21 or older
Current tobacco user
Exclusion Criteria:
Age less than 21
Addiction & Substance Abuse, Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  Show all 3 locations

Study Locations

Hide all locations
Location
Harrisburg, PA
Hershey, PA
York, PA

A Survey to Estimate the Socio-Economic Impact of the Novel Corona Virus (COVID-19) Pandemic

We are experiencing global outbreak of coronavirus (COVID-19) recently. Millions of people are suffering and dying every day, in spite of putting our best efforts. We are doing this survey to understand people’s reaction to this situation. The survey will ask about your knowledge, practices and worries. Your response will help us to understand how to better control these situations. Your feedback is highly important to us, as we need to find out the best way to stop the disease from spreading and killing thousands of lives, and to reduce the stress among the population.
Pritish Mondal at pmondal@pennstatehealth.psu.edu or 717-897-0652
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
General population
Adult
Exclusion Criteria:
Age below 18 years
Mentally impaired
Infectious Diseases & Immune System, Prevention, Lung Disease & Asthma
  Email this study information to me
  Contact the study team